Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP3-Duo
- Development stage
- Preclinical
- Lead developer
- Serpin Pharma
- Modality
- Peptides
01
Overview
SP3-Duo is an early-stage synthetic peptide antibiotic candidate developed by Serpin Pharma. It is part of a proprietary platform of short peptides derived from Alpha-1 Antitrypsin (AAT), a natural serine protease inhibitor known for its anti-inflammatory and immunomodulatory properties. While Serpin Pharma's lead candidates, such as SP16, are designed to target the LRP1 receptor to resolve inflammation, SP3-Duo is specifically categorized in the company's pipeline for anti-infective applications. As of early 2024, the program is listed as being in the 'stem for partnering' phase, indicating it is available for licensing or collaborative development.
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on SP3-Duo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP3-Duo.